Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for cardiovascular disease
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cardiovascular disease or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on cardiovascular disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
Usefulness of Multiple Biomarkers for Predicting Incident Major Adverse Cardiac Events in Patients Who Underwent Diagnostic Coronary Angiography (from the Catheter Sampled Blood Archive in CardiovascularDiseases [CASABLANCA] Study) 28487034 2017 05 10 2017 06 12 1879-1913 120 1 2017 Jul 01 The American journal of cardiology Am. J. Cardiol. Usefulness of Multiple Biomarkers for Predicting Incident Major Adverse Cardiac Events in Patients Who Underwent Diagnostic Coronary Angiography (from (...) the Catheter Sampled Blood Archive in CardiovascularDiseases [CASABLANCA] Study). 25-32 S0002-9149(17)30636-7 10.1016/j.amjcard.2017.03.265 We sought to develop a multiple biomarker approach for prediction of incident major adverse cardiac events (MACE; composite of cardiovascular death, myocardial infarction, and stroke) in patients referred for coronary angiography. In a 649-participant training cohort, predictors of MACE within 1 year were identified using least-angle regression; over 50 clinical
Cardiovascular and neuropsychiatric risks of varenicline and bupropion in smokers with chronic obstructive pulmonary disease 28473506 2017 05 05 2017 05 05 1468-3296 2017 May 04 Thorax Thorax Cardiovascular and neuropsychiatric risks of varenicline and bupropion in smokers with chronic obstructive pulmonary disease. thoraxjnl-2017-210067 10.1136/thoraxjnl-2017-210067 Varenicline and bupropion are effective smoking cessation treatments, but there are concerns about their safety in smokers (...) with COPD. To investigate whether varenicline and bupropion are associated with serious adverse cardiovascular and neuropsychiatric events in smokers with COPD. In a retrospective cohort study, we used data from 14 350 patients with COPD included in the QResearch database, which holds data from 753 National Health Service general practices across England. We identified patients with COPD who received a prescription of nicotine replacement therapy (NRT; N=10 426; reference group), bupropion (N=350
Genetic and Pharmacologic Inactivation of ANGPTL3 and CardiovascularDisease. Background Loss-of-function variants in the angiopoietin-like 3 gene (ANGPTL3) have been associated with decreased plasma levels of triglycerides, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol. It is not known whether such variants or therapeutic antagonism of ANGPTL3 are associated with a reduced risk of atherosclerotic cardiovasculardisease. Methods We sequenced the exons (...) with decreased levels of all three major lipid fractions and decreased odds of atherosclerotic cardiovasculardisease. (Funded by Regeneron Pharmaceuticals and others; ClinicalTrials.gov number, NCT01749878 .).
Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovasculardisease: prospective cohort study. Objectives To develop and validate updated QRISK3 prediction algorithms to estimate the 10 year risk of cardiovasculardisease in women and men accounting for potential new risk factors. Design Prospective open cohort study. Setting General practices in England providing data for the QResearch database. Participants 1309 QResearch general practices (...) in England: 981 practices were used to develop the scores and a separate set of 328 practices were used to validate the scores. 7.89 million patients aged 25-84 years were in the derivation cohort and 2.67 million patients in the validation cohort. Patients were free of cardiovasculardisease and not prescribed statins at baseline. Methods Cox proportional hazards models in the derivation cohort to derive separate risk equations in men and women for evaluation at 10 years. Risk factors considered
Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease. BACKGROUND: The cholesteryl ester transfer protein inhibitor evacetrapib substantially raises the high-density lipoprotein (HDL) cholesterol level, reduces the low-density lipoprotein (LDL) cholesterol level, and enhances cellular cholesterol efflux capacity. We sought to determine the effect of evacetrapib on major adverse cardiovascular outcomes in patients with high-risk vascular disease. METHODS: In a multicenter (...) effects on established lipid biomarkers, treatment with evacetrapib did not result in a lower rate of cardiovascular events than placebo among patients with high-risk vascular disease. (Funded by Eli Lilly; ACCELERATE ClinicalTrials.gov number, NCT01687998 .).
Association between active commuting and incident cardiovasculardisease, cancer, and mortality: prospective cohort study. Objective To investigate the association between active commuting and incident cardiovasculardisease (CVD), cancer, and all cause mortality. Design Prospective population based study. Setting UK Biobank. Participants 263 450 participants (106 674 (52%) women; mean age 52.6), recruited from 22 sites across the UK. The exposure variable was the mode of transport used
Mortality and CardiovascularDisease in Type 1 and Type 2 Diabetes. BACKGROUND: Long-term trends in excess risk of death and cardiovascular outcomes have not been extensively studied in persons with type 1 diabetes or type 2 diabetes. METHODS: We included patients registered in the Swedish National Diabetes Register from 1998 through 2012 and followed them through 2014. Trends in deaths and cardiovascular events were estimated with Cox regression and standardized incidence rates. For each (...) patient, controls who were matched for age, sex, and county were randomly selected from the general population. RESULTS: Among patients with type 1 diabetes, absolute changes during the study period in the incidence rates of sentinel outcomes per 10,000 person-years were as follows: death from any cause, -31.4 (95% confidence interval [CI], -56.1 to -6.7); death from cardiovasculardisease, -26.0 (95% CI, -42.6 to -9.4); death from coronary heart disease, -21.7 (95% CI, -37.1 to -6.4
Effect of Baseline Nutritional Status on Long-term Multivitamin Use and CardiovascularDisease Risk: A Secondary Analysis of the Physicians' Health Study II Randomized Clinical Trial. 28384735 2017 04 06 2017 04 06 2380-6591 2017 Apr 05 JAMA cardiology JAMA Cardiol Effect of Baseline Nutritional Status on Long-term Multivitamin Use and CardiovascularDisease Risk: A Secondary Analysis of the Physicians' Health Study II Randomized Clinical Trial. 10.1001/jamacardio.2017.0176 Long-term (...) multivitamin use had no effect on risk of cardiovasculardisease (CVD) in the Physicians' Health Study II. Baseline nutritional status may have modified the lack of effect. To investigate effect modification by various baseline dietary factors on CVD risk in the Physicians' Health Study II. The Physicians' Health Study II was a randomized, double-blind, placebo-controlled trial testing multivitamin use (multivitamin [Centrum Silver] or placebo daily) among US male physicians. The Physicians' Health Study
Effect of Monthly High-Dose Vitamin D Supplementation on CardiovascularDisease in the Vitamin D Assessment Study : A Randomized Clinical Trial. 28384800 2017 04 06 2017 04 06 2380-6591 2017 Apr 05 JAMA cardiology JAMA Cardiol Effect of Monthly High-Dose Vitamin D Supplementation on CardiovascularDisease in the Vitamin D Assessment Study : A Randomized Clinical Trial. 10.1001/jamacardio.2017.0175 Cohort studies have reported increased incidence of cardiovasculardisease (CVD) among individuals
Tachykinin neurokinin 3 receptor antagonists: a new treatment for cardiovasculardisease? Great progress has been made in reducing cardiovascular mortality over the past 50 years. Nevertheless, prevalence is rising in some settings and remains higher in men than in women, even with the same level of established risk factors. To gain new insights, researchers are now considering cardiovasculardisease in relation to the well known evolutionary biology model of growth and reproduction trading off (...) against longevity, with trials of calorie restriction underway. However, calorie restriction has not been as successful as expected in primates and it is increasingly realised that effects on the reproductive axis might also be important. In this paper, the modulation of the reproductive axis using existing agents that have such properties-tachykinin neurokinin 3 receptor antagonists-is proposed as a way of reducing cardiovasculardisease and combating a leading cause of global morbidity and mortality
Association between clinically recorded alcohol consumption and initial presentation of 12 cardiovasculardiseases: population based cohort study using linked health records. Objectives To investigate the association between alcohol consumption and cardiovasculardisease at higher resolution by examining the initial lifetime presentation of 12 cardiac, cerebrovascular, abdominal, or peripheral vascular diseases among five categories of consumption.Design Population based cohort study of linked (...) electronic health records covering primary care, hospital admissions, and mortality in 1997-2010 (median follow-up six years).Setting CALIBER (ClinicAl research using LInked Bespoke studies and Electronic health Records).Participants 1 937 360 adults (51% women), aged ≥30 who were free from cardiovasculardisease at baseline.Main outcome measures 12 common symptomatic manifestations of cardiovasculardisease, including chronic stable angina, unstable angina, acute myocardial infarction, unheralded
Evolocumab and Clinical Outcomes in Patients with CardiovascularDisease. Background Evolocumab is a monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) and lowers low-density lipoprotein (LDL) cholesterol levels by approximately 60%. Whether it prevents cardiovascular events is uncertain. Methods We conducted a randomized, double-blind, placebo-controlled trial involving 27,564 patients with atherosclerotic cardiovasculardisease and LDL cholesterol levels (...) and neurocognitive events), with the exception of injection-site reactions, which were more common with evolocumab (2.1% vs. 1.6%). Conclusions In our trial, inhibition of PCSK9 with evolocumab on a background of statin therapy lowered LDL cholesterol levels to a median of 30 mg per deciliter (0.78 mmol per liter) and reduced the risk of cardiovascular events. These findings show that patients with atherosclerotic cardiovasculardisease benefit from lowering of LDL cholesterol levels below current targets
Uses of polypills for cardiovasculardisease and evidence to date. Polypills have been approved in more than 30 countries, but worldwide experience with and availability of polypills remain limited, unlike fixed-dose combinations in other diseases such as HIV, tuberculosis, and malaria. In this Series review, we aim to propose a guide for the use of polypills in future research and clinical activities and to synthesise contemporary evidence supporting the use of polypills for prevention
Renocardiovascular Biomarkers: from the Perspective of Managing Chronic Kidney Disease and CardiovascularDisease 28321399 2018 11 13 2297-055X 4 2017 Frontiers in cardiovascular medicine Front Cardiovasc Med Renocardiovascular Biomarkers: from the Perspective of Managing Chronic Kidney Disease and CardiovascularDisease. 10 10.3389/fcvm.2017.00010 Mortality among the patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD) remains high because of the very high incidence (...) of cardiovasculardisease (CVD) such as coronary artery disease, cardiac hypertrophy, and heart failure. Identifying CVD in patients with CKD/ESRD remains a significant hurdle and the early diagnosis and therapy for CVD is crucial in these patients. Therefore, it is necessary for the better management to identify and utilize cardiovascular (CV) biomarkers in profiling CVD risk and enabling stratification of early mortality. This review summarizes current evidence about renocardiovascular biomarkers: CV
Disaggregation of Cause-Specific CardiovascularDisease Mortality Among Hispanic Subgroups 28114655 2018 11 13 2380-6591 2 3 2017 Mar 01 JAMA cardiology JAMA Cardiol Disaggregation of Cause-Specific CardiovascularDisease Mortality Among Hispanic Subgroups. 240-247 10.1001/jamacardio.2016.4653 Hispanics are the largest minority group in the United States and face a disproportionate burden of risk factors for cardiovasculardisease (CVD) and low socioeconomic position. However, Hispanics (...) extracted from the US National Center for Health Statistics mortality records using the underlying cause of death based on coding from the International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (I00-II69). Mortality data were evaluated from January 1, 2003, to December 31, 2012. Population estimates were calculated using linear interpolation from the 2000 and 2010 US Census reports. Data were analyzed from November 2015 to July 2016. Mortality due to CVD
Diabetes, kidney disease and cardiovascular outcomes in the Jackson Heart Study 28002548 2018 11 13 2380-6591 2 3 2017 Mar 01 JAMA cardiology JAMA Cardiol Absolute Rates of Heart Failure, Coronary Heart Disease, and Stroke in Chronic Kidney Disease: An Analysis of 3 Community-Based Cohort Studies. 314-318 10.1001/jamacardio.2016.4652 Cardiovasculardisease is the leading cause of morbidity and mortality in patients with chronic kidney disease (CKD). Understanding the relative contributions (...) of cardiovasculardisease event types to the excess burden of cardiovasculardisease is important for developing effective strategies to improve outcomes. To determine absolute rates and risk differences of incident heart failure (HF), coronary heart disease (CHD), and stroke in participants with vs without CKD. We pooled participants without prevalent cardiovasculardisease from 3 community-based cohort studies: the Jackson Heart Study, Cardiovascular Health Study, and Multi-Ethnic Study of Atherosclerosis
Prevalence of metabolic syndrome and degree of cardiovasculardisease risk in patients with Psoriatic Arthritis 28293452 2018 11 13 2147-9720 4 1 2017 Mar European journal of rheumatology Eur J Rheumatol Prevalence of metabolic syndrome and degree of cardiovasculardisease risk in patients with Psoriatic Arthritis. 40-45 10.5152/eurjrheum.2017.16052 The aim of this study was to identify the prevalence of metabolic syndrome (MetS) and degree of cardiovasculardisease (CVD) risk in patients (...) , Turkey; Division of Rheumatology, Department of Internal Medicine, Akdeniz University School of Medicine, Antalya, Turkey. eng Journal Article 2017 03 01 Turkey Eur J Rheumatol 101656068 2147-9720 Eur J Rheumatol. 2017 Dec;4(4):307 29308291 Psoriatic arthritis cardiovasculardisease coronary heart disease metabolic syndrome rheumatoid arthritis Conflict of Interest: No conflict of interest was declared by the authors. 2016 06 18 2016 11 17 2017 3 16 6 0 2017 3 16 6 0 2017 3 16 6 1 ppublish 28293452
Multidimensional Integrative Genomics Approaches to Dissecting CardiovascularDisease 28289683 2018 11 13 2297-055X 4 2017 Frontiers in cardiovascular medicine Front Cardiovasc Med Multidimensional Integrative Genomics Approaches to Dissecting CardiovascularDisease. 8 10.3389/fcvm.2017.00008 Elucidating the mechanisms of complex diseases such as cardiovasculardisease (CVD) remains a significant challenge due to multidimensional alterations at molecular, cellular, tissue, and organ levels (...) Angeles, Los Angeles, CA, USA; Institute for Quantitative and Computational Biosciences, University of California Los Angeles, Los Angeles, CA, USA; Molecular Biology Institute, University of California Los Angeles, Los Angeles, CA, USA. eng R01 DK104363 DK NIDDK NIH HHS United States Journal Article Review 2017 02 27 Switzerland Front Cardiovasc Med 101653388 2297-055X cardiovasculardisease epigenomics genomics integrative genomics metabolomics multidimensional omics integration proteomics
The effect of Hepatitis C Virus infection on cardiovascular complications in end stage kidney disease patients on regular hemodialysis 28465818 2018 11 13 2008-5842 9 2 2017 Feb Electronic physician Electron Physician The effect of Hepatitis C Virus infection on cardiovascular complications in end stage kidney disease patients on regular hemodialysis. 3857-3861 10.19082/3857 Cardiovascular complications are the most important cause of mortality in patients with ESKD, such as coronary artery disease (...) , left ventricular hypertrophy, heart failure and arrhythmia. Other well-known risk factors, such as diabetes mellitus, hypertension and dyslipidemia are prevalent in ESKD, yet they are not sufficient enough to explain the high prevalence of cardiovascular mortality, hence searching for other hidden risk factors to explain this high prevalence is of an utmost importance. The aim of this study was to identify the exact mechanisms connecting HCV infection, chronic liver disease, and atherogenesis